RR variability (HRV), an independent predictor of death following myocardial infarction, may also be related to other features of coronary artery disease. We evaluated its ability to differentiate among sedentary patients with chest pain ≥45 years of age demonstrating either normal or abnormal myocardial perfusion with rest and exercise thallium-210 tomographic imaging. The major HRV difference between 48 men and 50 women with normal perfusion was a significantly higher high frequency power in women. No significant differences in mean HRV values were found between the 57 men with abnormal perfusion scans and the 48 men with normal perfusion. In both men and women with normal perfusion scans, duration of exercise was significantly related to age. In men with abnormal scans, impaired myocardial perfusion alters the relationship between exercise duration and age, and a group of individuals with diminished HRV and low levels of physical fitness, regardless of age, can be identified. Despite these latter selective findings, we conclude that HRV is not a sensitive indicator to differentiate patients with normal and abnormal myocardial perfusion.

1.
Luria MH, Sapoznikov D, Gilon D, Zahger D, Weinstein JM, Weiss AT, Gotsman MS: Early heart rate variability alterations after acute myocardial infarction. Am Heart J 1993;125:676–681.
2.
Bigger JT, Fleiss JL, Steinman RC, Rolnitzky LM, Schneider WJ, Stein PK: RR variability in healthy, middle-aged persons compared with patients with chronic coronary heart disease or recent acute myocardial infarction. Circulation 1995;91:1936–1943.
3.
Hayano J, Sakakibara Y, Yamada M, Ohte N, Fujinami T, Yokoyama K, Watanbe Y, Takata K: Decreased magnitude of heart rate spectral components in coronary artery disease: Its relation to angiographic severity. Circulation 1990;81:1217–1224.
4.
Jensen-Urstad M, Jensen-Urstad K, Ericson M, Johansson J: Heart rate variability is related to leucocyte count in men and to blood lipoproteins in women in a healthy population of 35-year-old subjects. J Intern Med 1998;243:33–40.
5.
Goldsmith RL, Bloomfield DM, Steinman RC, Bigger JT: Ultra low frequency power is the only power spectral measure not confounded by physical fitness. J Am Coll Cardiol 1996;27(supplement A):95A.
6.
Sapoznikov D, Luria MH, Mahler Y, Gotsman MS: Computer processing of artifact and arrhythmias in heart rate variability analysis. Comput Methods Programs Biomed 1992;39:75–84.
7.
Sapoznikov D, Luria MH, Mahler Y, Gotsman MS: Day vs night ECG and heart rate variability patterns in patients without obvious heart disease. J Electrocardiol 1992;25:175–184.
8.
Sinnreich R, Kark JD, Friedlander Y, Sapoznikov D, Luria MH: Five minute recordings of heart rate variability for population studies: Repeatability and age-sex characteristics. Heart 1998;80:156–162.
9.
Ryan SR, Goldberger AL, Pincus SM, Mietus J, Lipsitz LA: Gender- and age-related differences in heart rate dynamics. Are women more complex than men? J Am Coll Cardiol 1994;24:1700–1707.
10.
Yataco AR, Fleisher LA, Katzel LI: Heart rate variability and cardiovascular fitness in senior athletes. Am J Cardiol 1997;80:1389–1391.
11.
Davy KP, Desouza CA, Jones PP, Seals DR: Elevated heart rate variability in physically active young and older adult women. Clin Sci 1998;94:579–584.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.